A total of 20 patients were included in the safety run-in cohort and completed preliminary evaluation. Results demonstrated that Opamtistomig in combination with chemotherapy was generally well ...
Boehringer Ingelheim today announced a clinical trial collaboration with BioNTech to evaluate a novel immuno--oncology combination in extensive--stage small cell lung cancer (ES-SCLC), one of the most ...
Population Relevance, Histology, and PD-L1 Considerations, our panel delve into the following critical questions: Is the ...
BostonGene, developer of the leading AI foundation model for tumor and immune biology, and ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today ...
In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it covers 14 indications across eight tumour types.
Keytruda's first approval by US FDA came in the year 2014 for advanced skin cancer. Now, the immunotherapy drug is being used ...
Boehringer Ingelheim to evaluate combination of DLL3-targeting T-cell engager plus PD-L1/VEGF-A bispecific antibody in small cell lung cancer: Ingelheim, Germany Saturday, April 1 ...
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it ...
Kazia Therapeutics is paying $1.4 million upfront to secure a platform for generating epigenetic drugs from an Australian research institute. Brisbane-based QIMR Berghofer develop ...
Kazia Therapeutics Limited , a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment resistance, announces the in-licensing of a first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results